Mindset Wealth Management LLC Purchases 2,875 Shares of Omeros Co. (NASDAQ:OMER)

Mindset Wealth Management LLC raised its position in Omeros Co. (NASDAQ:OMER) by 4.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,875 shares during the quarter. Mindset Wealth Management LLC’s holdings in Omeros were worth $622,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of OMER. Truvestments Capital LLC raised its position in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,669 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. Picton Mahoney Asset Management raised its position in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. MML Investors Services LLC raised its position in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares during the last quarter. Finally, US Bancorp DE bought a new position in shares of Omeros during the fourth quarter worth about $81,000. 48.79% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OMER has been the subject of several recent analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Thursday, February 20th. StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Trading Up 1.3 %

Shares of Omeros stock opened at $9.10 on Friday. The business’s fifty day simple moving average is $8.70 and its 200 day simple moving average is $7.28. The firm has a market capitalization of $527.35 million, a P/E ratio of -3.94 and a beta of 2.03. Omeros Co. has a 12 month low of $2.61 and a 12 month high of $13.60.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.